|
|
MCL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring
The rapid evolution of treatment advances in mantle cell lymphoma (MCL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy.
This activity has been developed to help cl... |
|
|
CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring
The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing therapy), duration of treatment, management of treatment-related toxicities, and disease outcomes across... |
|
|
RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL
With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly.
In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to several of the most consequential changes in CLL/MCL patient care, including diagnostic and prognostic... |
|
|
Optimizing Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
The rapid evolution of treatment advances in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL and CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy.
... |
|
|
Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia
Target Audience
This education activity is directed towards OB-GYNs, medical oncologists, surgical oncologists, radiation oncologists, primary care physicians, such as family practitioners and internists, and radiologists.
Program Overview
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma and is a distinct entity from systemic ALCL. In the United States, the FDA began to recognize reports of ALCL and a potential association with breast impla... |
|
|
Osler Radiation Oncology Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|
|
Osler Surgery MOC Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|